Japan Rheumatoid Arthritis Therapeutics Market Size & Outlook

The rheumatoid arthritis therapeutics market in Japan is expected to reach a projected revenue of US$ 1,480.1 million by 2030. A compound annual growth rate of 5.5% is expected of Japan rheumatoid arthritis therapeutics market from 2024 to 2030.
Revenue, 2023 (US$M)
$1,014.7
Forecast, 2030 (US$M)
$1,480.1
CAGR, 2024 - 2030
5.5%
Report Coverage
Japan

Japan rheumatoid arthritis therapeutics market, 2018-2030 (US$M)

Japan

Related Markets

Japan rheumatoid arthritis therapeutics market highlights

  • The Japan rheumatoid arthritis therapeutics market generated a revenue of USD 1,014.7 million in 2023 and is expected to reach USD 1,480.1 million by 2030.
  • The Japan market is expected to grow at a CAGR of 5.5% from 2024 to 2030.
  • In terms of segment, biopharmaceuticals was the largest revenue generating molecule in 2023.
  • Biopharmaceuticals is the most lucrative molecule segment registering the fastest growth during the forecast period.


Rheumatoid arthritis therapeutics market data book summary

Market revenue in 2023USD 1,014.7 million
Market revenue in 2030USD 1,480.1 million
Growth rate5.5% (CAGR from 2023 to 2030)
Largest segmentBiopharmaceuticals
Fastest growing segmentBiopharmaceuticals
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationPharmaceuticals, Biopharmaceuticals
Key market players worldwideBoehringer Ingelheim, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Pfizer Inc, Bristol-Myers Squibb Co, Roche Holding AG, UCB SA, Johnson & Johnson, Amgen Inc, AbbVie Inc


Other key industry trends

  • In terms of revenue, Japan accounted for 4.1% of the global rheumatoid arthritis therapeutics market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, China rheumatoid arthritis therapeutics market is projected to lead the regional market in terms of revenue in 2030.
  • China is the fastest growing regional market in Asia Pacific and is projected to reach USD 2,006.3 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Rheumatoid Arthritis Therapeutics Market Companies

Name Profile # Employees HQ Website

Japan rheumatoid arthritis therapeutics market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rheumatoid arthritis therapeutics market will help companies and investors design strategic landscapes.


Biopharmaceuticals was the largest segment with a revenue share of 88.71% in 2023. Horizon Databook has segmented the Japan rheumatoid arthritis therapeutics market based on pharmaceuticals, biopharmaceuticals covering the revenue growth of each sub-segment from 2018 to 2030.


The Japan rheumatoid arthritis therapeutics market has seen a significant development with the approval of METOJECT Subcutaneous Injection Syringe (methotrexate) for treating RA. This approval, announced in September 2022 by Eisai Co., Ltd. and Nippon Medac Co., Ltd., marked the introduction of the first self-administrable methotrexate subcutaneous injection formulation for RA in Japan.

The approval of METOJECT offers a new treatment option for RA patients in Japan and addresses the need for convenient & effective self-administration methods. This development is expected to positively impact the RA therapeutics market in Japan by providing patients with a more accessible and user friendly treatment option.

Furthermore, the collaboration between Eisai and Nippon Medac, facilitated by a license agreement signed in 2019, highlights the importance of partnerships and collaborations in driving innovation & expanding treatment options in the RA therapeutics market.

Reasons to subscribe to Japan rheumatoid arthritis therapeutics market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Japan rheumatoid arthritis therapeutics market databook

  • Our clientele includes a mix of rheumatoid arthritis therapeutics market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Japan rheumatoid arthritis therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Japan rheumatoid arthritis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Japan rheumatoid arthritis therapeutics market size, by molecule, 2018-2030 (US$M)

Japan Rheumatoid Arthritis Therapeutics Market Share, 2023 & 2030 (US$M)

Japan rheumatoid arthritis therapeutics market size, by molecule, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more